First human test of new fatty liver pill begins
NCT ID NCT07462455
Summary
This is an early-stage study to check the safety and basic effects of a new oral drug called ACT500 in people with fatty liver disease linked to metabolic problems like obesity or diabetes. About 24 participants will take the pill daily at different dose levels to see how their bodies handle it. The main goal is to find out if it's safe and well-tolerated, while also measuring initial changes in liver fat and other health markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua Changgeng Hospital
Beijing, China
Contact
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Contact
-
The First Affiliated Hospital of Xiamen University
Xiamen, China
Contact
-
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact
Conditions
Explore the condition pages connected to this study.